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INTRODUCTION 
 
Cardiovascular disease (CVD), principally due to 
atherosclerosis, remains the largest cause of death and 
therefore influences longevity in the US [1,2]. This also 
applies to other middle/high-income countries. Two 
large meta-analyses have concluded that short leukocyte 
telomere length (LTL) is associated with CVD [3,4], 
while other studies [5-8], including a meta-analysis [9], 
have shown that short LTL predicts diminished 
longevity. Thus, the association between short LTL and 
diminished longevity might relate in part to the 
association of short LTL with CVD. Moreover, genetic 
analyses have revealed that alleles associated with short 
LTL are also associated with CVD [10-12], largely 
excluding the possibility of reverse causality, i.e., CVD 
causing LTL shortening. Coupled with observations that 
LTL, which reflects telomere length in somatic tissues 
[13], is highly heritable [14,15] and is largely 
determined at birth [16], these findings suggest that 
telomere length might play an active role in CVD and 
longevity. Such a conclusion is relevant to the debate 
about the existence of a natural lifespan limit for 
humans [17-21]. Here we show that in some individuals 
LTL becomes critically short at an age younger than 
that of the current life expectancy. Moreover, we show 
that with predicted upward trajectories of life 
expectancy, the proportion of these individuals will only 




We examined the potential role of telomere length in 
human longevity in two settings: contemporary life 
expectancy, and life expectancy of 100 years (LE-100) 
i.e., assuming survival until the age of 100 years [17].  
To this end, we first defined the LTL threshold below 
which the probability of survival substantially declines. 
We refer to this threshold as the ‘telomeric brink’ (TB).  
 
Figure 1 is a composite that illustrates the relation 
between LTL, measured in the same laboratory, and age 
for whites of European ancestry residing in Denmark 
(n=1,727), France (n=185), Italy (n=548), the UK 
(n=3,514), the USA (n=5,726), and Jews in Israel 
(n=620). Characteristics of these subjects are displayed 
in Table 1S. The scatter plots (Figure 1, top panels) 
show that LTL progressively becomes shorter with age 
and that it varies widely between individuals of the 
same age. 
  
To establish a reference for a critically short LTL that 
engenders a considerable risk of imminent death, i.e., 
the TB, we measured LTL (in the same laboratory that 
generated the LTL data displayed in Figure 1) in 
individuals suffering from dyskeratosis congenita (DC) 
and their unaffected relatives. DC, the outcome of rare 
germline mutations, is expressed in extremely short 
telomere length, which is the main cause of the patients’ 
premature demise [22]. In patients with DC the mean 
LTL was 4.99 kb, while in relatives it was 6.49 kb 
(p<0.0001) (Table 2S).  
 
Although DC and related telomere disorders [23] unfold 
under different circumstances from those experienced 
by the individuals with short telomeres in late life, for 
the following reason LTL of 5 kb is a reasonable cutoff 
point to define a critically short LTL: Only 0.78%, of 
live subjects younger than 90 years displayed LTL ≤ 5 
kb (Figure 1 top panel). In the oldest old, i.e., between 
the ages of 95-105 years, where mortality rate is very 
high, 37% (95% CI: 30-44%) of females showed an 
LTL ≤ 5 kb, compared with 58% (95% CI: 43-72%) of 
males (p=0.009 by Fisher's exact test). These cross-
sectional data provide no direct information about 
selective survival with respect to LTL. A variance-ratio 
test suggests, however, that this might be the case 
(Figure 1, bottom panels), as, for instance, individuals 
aged 100 (95-105) years displayed less LTL variance 
than those aged 50 (45-55) years (variance ratios of 1.60 
for males, p = 0.048; variance ratio of 1.36 for females, 
p = 0.011). 
 
Figure 1 does not offer information that foretells if a 
person whose LTL is, for instance, 6.4 kb at the age of 
35 years could reach his/her life expectancy before 
crossing the TB. However, with information from life 
tables [24], combined with the known rate of telomere 
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for a 100‐year  life expectancy. Thus secular trends  in  life expectancy should confront a biological  limit due to
crossing the telomeric brink.  
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shortening with age [25], we estimated the proportion of 
individuals reaching the TB during their predicted life 
expectancy. We also calculated the proportion of 
individuals reaching the TB for LE-100. This estimated 
proportion indicates to what extent living to 100 years 
may be constrained by LTL.  
 
We computed the proportion of our composite study 
sample that would reach the TB based on the baseline 
LTL for four age groups, 35 (30-40), 50 (45-55), 65 
(60-70) and 80 (75-85) years, and for different LTL 
attrition rates (Materials and Methods). Our initial 
computations were strictly based on the empirical data 
displayed in Figure 1 and the assumption of a constant 
rate of age-dependent LTL attrition for a given 
individual. For individuals who had already crossed the 
TB at baseline, we let the TB age be equal to their age 
at blood collection. We then found the individual’s 





































corresponding period life table [24], based on the 
nationality, sex and age of the individual and the date of 
blood collection. By taking the mean of the individual 
probabilities of reaching an LTL= 5 kb, we determined 
the overall probability of reaching the TB for a given 
LTL attrition rate. We used the same approach to 
quantify the probability of reaching the TB before the 
LE-100, except that instead of using period life table 
mortality, we used a lifespan of exactly 100 years. Thus, 
an individual is judged to have reached the TB age if 
his/her LTL becomes shorter than 5 kb before the age of 
100 years.  
 
Younger subjects (ages 35 and 50 years) in the samples 
displayed in Figure 1, whose LTL attrition is > 30 
bp/year, already run some risk of reaching the TB based 
on period mortality (Figure 2). This risk escalates for 
LE-100, such that even individuals whose LTL attrition 








































in different countries (Supplemental Table 1). The horizontal dashed  lines  in the top panels and vertical dashed  lines  in the
bottom panels indicate LTL values of 5 kb. The bottom plots are smoothed histograms obtained by kernel density estimation.
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that a longer life expectancy entails a greater chance of 
reaching the TB, the increased probability of reaching the 
TB based on LE-100 is expected, but what is relevant 
here is that this effect is of quantitative importance. 
 
Females typically have a longer LTL than males [26]. 
Females of modern societies also outlive males by 
approximately 5 years [24,27]. The Human Mortality 
Database for 2010 [24] indicates, for instance, that on 
the average, a Danish female dies at 81.3 years, while 
Danish male dies at 77.1 years; a French female dies at 
84.7 years, while a French male dies at 78.0 years. 
Typically, females display an age-adjusted LTL that is 
approximately 150 bp longer than that of males (data 
presented in Table 1S are not adjusted for age). We 
examined, therefore, the impact of sex on the 
probability of reaching the TB (Figure 3). For period 
life table mortality, the probabilities for males and 
females of reaching the TB are almost identical. 
However, for the fixed LE-100, the probability of 



































Thus far, we presented the population average 
probability of reaching the TB, but this probability is 
likely to be heterogeneous, depending on the initial 
LTL. Adults typically display strong tracking of LTL, 
such that compared with peers, the individual’s LTL is 
virtually anchored to a given LTL rank at least over the 
course of up to 13 years of follow-up [28].  We 
attributed this phenomenon to the outsized influence of 
the inter-individual variation in LTL at birth and to a 
lesser extent to the inter-individual variation in LTL 
attrition during growth on the individual’s LTL 
throughout the life course [16]. We therefore examined 
the impact of LTL ranking by quintiles (1st quintile, 
shortest LTL; 5th quintile, longest LTL) on the 
probability of the individual reaching an LTL of 5 kb 
during his/her future life course.  We observed that 
having an LTL ranked in the lower two quintiles of the 
LTL distribution significantly increased the probability 
of reaching the TB as compared to the higher quintiles, 







































5 kb) based on period  life table mortality  (period),  life expectancy of 100 years  (LE‐100) and LTL
attrition. The panels display findings for four age groups: 35 years (range 30‐40 years); 50 years (range 45‐55
years); 60 years (range 55‐65 years); 80 years (range 75‐85 years), based on different LTL attrition rates (15‐45
bp/year).  For period mortality,  the proportion  (in %) of  individuals  reaching  an  LTL of 5  kb before  their  life
expectancy is based on the aggregate mortality data for a given country and sex at the time of blood collection.







































The probabilities displayed in Figures 2-4 underscore 
that a subset of the general population might reach the 
TB at present life expectancies and more so at LE-100. 
However, they are based on constant rates of LTL 
attrition throughout the adult life course. In reality, the 
individual’s rate of LTL attrition probably fluctuates.  
Accordingly, we have also modeled the probability of 
reaching the TB with a theoretical distribution for the 
yearly LTL attrition based on randomized, variable LTL 
attrition rates over a 10-year LTL shortening of 300 bp 
± 150 bp (SD) [25].   
 
Table 1 displays the aggregate findings for the 
probability of reaching the TB inferred for the general 
population and the five LTL ranking quintiles. In this 
setting, for instance, a 35 year-old individual has a 14% 
and 39% probability of reaching the TB for period 







































ked in the lowest (1st) quintile of the LTL distribution 
has a 50% and a 93% probability of reaching the TB for 
period mortality and LE-100, respectively. We note that 
the dataset is a composite of studies comprising 
individuals of different age groups and nations (Figure 
1). Thus, some of the small variations in the probability 
of reaching the TB for “All” and specific quintiles in 
Table 1 might reflect different mean ages of mortality in 
different nations. The relevant comparisons of interest 
are between period mortality and LE-100 and between 




Our analysis suggests that the individual’s LTL, as 
reflected in his/her ranking, may be a major determinant 
of that individual’s natural lifespan limit from the 
standpoint of telomere biology. Clearly, the link 
Figure 3. Predicted proportion of the composite study population of males and females reaching the telomere
brink (TB; 5 kb) based on period life table mortality (period), life expectancy of 100 years (LE‐100), LTL ranking
and  LTL attrition. The panels display  findings  for  four  age  groups: 35  years  (range 30‐40  years); 50  years  (range 45‐55
years); 60 years (range 55‐65 years); 80 years (range 75‐85 years), based on different LTL attrition rates (15‐45 bp/year). 
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between LTL and human longevity is more complex, 
since telomere biology might also contribute to human 
aging and longevity by mechanisms additional to a 
probability of having critically short telomeres that 
impact cell viability and the individual’s survival. For 
instance, age-dependent telomere shortening might alter 
gene expression in sub-telomeric regions [29], thus 
influencing aging and longevity. Moreover, double 
stranded DNA breaks in telomeres are irreparable and 
can bring about cell senescence and affect cellular 
viability when TL is not critically short [30]. That said, 
the TB concept underscores the fact that critically short 
telomeres can be reached in a subset of the general 
population for current life expectancy and in a 
substantially larger proportion for the LE-100. 
 
Demonstrating that for period life table mortality the 







































females suggests that the female life expectancy 
advantage is approximately equivalent in terms of 
telomeric attrition years to the LTL sex gap. For 
instance, assuming tha females live 5 years longer than 
males, an LTL that is longer by 150 bp in females 
amounts to 5 years of telomeric equivalence for an 
average of 30 bp/year LTL attrition rate during adult-
hood.  Further support for this thesis is provided by the 
trajectories based on the fixed LE-100. As females have 
a longer LTL than males, their risk of reaching the TB 
is smaller than that of males within a 100-year lifespan. 
Empirical data displayed in Figure 1 support this thesis; 
between the ages of 95-105 years, the fraction of males 
who have reached the TB of 5 kb is considerably higher 
than that of females. Collectively, these findings point 










































based on period  life  table mortality  (period),  life expectancy of 100 years  (LE‐100),  LTL  ranking and  LTL
attrition.  Individuals were ranked by quintiles, where the shortest (1st) LTL quintile  is 0‐19% and the  longest (5th) LTL
quintile  is 80‐99%. The panels display findings for four age groups: 35 years (range 30‐40 years); 50 years (range 45‐55
years); 60 years (range 55‐65 years); 80 years (range 75‐85 years), based on different LTL attrition rates (15‐45 bp/year). 






















Observing a nontrivial proportion with LTL ≤ 5 kb in 
the oldest old but not in the general population might 
stem from selection on two levels. First, in the context 
of current life expectancy, the oldest old are naturally a 
highly selected group. Their TB might be situated at 
lower LTLs. Second, epidemiological studies in the 
general population rarely recruit moribund, very sick 
individuals, who might display LTL ≤ 5 kb. However, 
studies of the oldest old rarely exclude participants in 
poor health. Therefore, if an LTL of 5 kb denotes a high 
probability of death or even imminent death, it is 
unlikely to be found in the general adult population but 
more likely to be found in the oldest old.  
 
In conclusion, at present, most individuals are not 
reaching the LTL brink during their life course, but our 
findings suggest that further extension in human 
longevity will be increasingly constrained by telomere 
length. This inference requires an assumption that a 
possible increase in telomere length at birth and a 
decrease in the average rate of telomere length attrition 
after birth in future generations will not offset this 
prediction. Notably, however, potential interventions to 
forestall the telomeric brink may have adverse 
consequences. While short LTL [3,4] and alleles 
associated with a shorter LTL [10-12] increase CVD 
risk, recent studies show that long LTL [31-34] and 
alleles associated with long LTL [12,35-38] increase 
risk of major cancers. Such findings beg the 
(evolutionary) question: Why is human telomere length 
as long as it is? Emerging data suggests that evolution 
has been fine-tuning our telomere length to balance 
cancer against degenerative diseases [39-41]. In 
contemporary humans, this balance has ostensibly 




















MATERIALS AND METHODS 
 
Subjects   
 
The LTL dataset was based on LTL measurements 
performed for cohorts participating in several studies 
[42-49]. Patients with DC and their unaffected relatives 
were participants in the National Cancer Institute’s Lon-
gitudinal Inherited Bone Marrow Failure Syndromes 
Study (NCI Protocol 02-C-0052, ClinicalTrials.gov 
Identifier NCT-00027274). DC patients included in this 
analysis had to have a germline mutation in one of the 
known causative DC genes and/or at least two features 
of the diagnostic triad (oral leukoplakia, reticular skin 
pigmentation, and/or nail dysplasia) along with other 
clinical findings consistent with DC. All relatives are 
mutation-negative except for 6/46 (13%); the probands 
in these 6 families are negative for known genes but 
have the diagnostic triad and other features consistent 
with DC. 
 
All subjects whose LTL data are summarized in Tables 
1S and 2S and those displayed in Figure 1 provided 
written informed consent approved by various 
institutional review boards and equivalent committees 
in the US, Europe and Israel. 
 
Measurements of LTL by Southern blots of the 
terminal restriction fragments  
 
These measurements were performed as previously 





Age (yrs) 35 50 65 80 
Life Expectancy (yrs) Period LE-100 Period LE-100 Period LE-100 Period LE-100 
All          (%) 14 39 8 27 6 20 10 24 
Prob Q1 (%) 50 93 34 83 25 73 45 88 
Prob Q2 (%) 16 62 6 37 3 21 4 28 
Prob Q3 (%) 5 30 1 12 0 5 0 5 
Prob Q4 (%) 1 10 0 2 0 1 0 1 
Prob Q5 (%) 0 1 0 0 0 0 0 0 
LTL=  leukocyte telomere  length; Period = mortality based on period  life tables; LE‐100 = expectancy of 100 years for 
all; Prob = probability of  reaching  the  telomeric brink; Q1 = 0‐19% of  the  LTL distribution, Q2 = 20‐39% of  the  LTL 
distribution,  Q3  =  40‐59%  of  the  LTL  distribution,  Q4  =  60‐79%  of  the  LTL  distribution,  Q5  =  80‐99%  of  the  LTL 
distribution. 
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Modeling 
 
For a chosen rate of attrition, we find each individual's 




where age is the age when the blood was collected. In 
case an individual has LTL < 5 kb, we let the TB age be 
the age at blood collection. The probability of survival 
until the TB age is determined through lookup in period 
life tables [24] or by assuming survival until the age of 
100 years. We aggregate the individual probabilities in 
order to find the overall probability of reaching the TB 
age. To construct Figures 2-4, we have used attrition 
rates of 15-45 bp/year in steps of 1 bp/year.  The 
smooth curves in Figures 2-4 were obtained by kernel 
smoothing of these point-estimates (normal kernel and a 
bandwidth of 5 bp/year). 
 
For illustration, consider a 50 year-old French woman 
who had blood drawn in 1998 for measurements of 
LTL. If this individual’s LTL was 6.1 kb and her 
constant attrition is assumed to be 30 bp/year, she 
would reach the TB of 5 kb after 37 years (her TB age 
is 87 years). The Human Mortality Database for French 
females in 1998 shows that 46% of women, aged 50 
years, live to be 87 or more. Thus, the probability for this 
50 year-old French woman of reaching the brink is 46%. 
 
We also modeled the probability of reaching the TB 
using a theoretical distribution of variable yearly LTL 
attrition. In order to find the aggregate probability of 
reaching the TB, we modeled the LTL attrition based on 
observations made in longitudinal studies with at least 
10 years of follow-up, because measurement errors of 
LTL in longitudinal studies of shorter duration might 
produce an artifact in the form of LTL elongation [25]. 
We chose to model changes to LTL as the sum of yearly 
independent attrition, where the yearly attrition (in bp) 
is drawn from a gamma distribution with shape 
parameter 0.4 and scale parameter 75. The shape and 
scale parameters were chosen such that the total LTL 
attrition after 10 years has a mean of 300 bp and an SD 
of 150 bp . The gamma distribution was chosen (Figure 
1S) because it gives a rather good fit to observed data 
from a comprehensive longitudinal study of approxi-
mately 12 years LTL attrition, where LTL was 
measured by Southern blots.  
 
This model enabled finding the theoretical LTL attrition 
distribution for any number of years after blood 
collection. When combined with mortality data, this 
approach allows us to effectively aggregate the curves 
in Figures 2 and 3 into single values for the probability 
of reaching the TB of 5 kb (Table 1) for each age group 
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Country/Sex N Telomere Length (kb) 
(2.5th - 97.5th percentile) 
Age (years) 
(2.5th - 97.5th percentile) 
Period* 
France/females 61 6.5  (5.5 – 7.6) 59  (37 – 75) 1998 
France/males 124 6.4  (5.3 – 7.5) 57  (38  – 74) 1998 
Denmark/females 1159 6.3  (4.7 – 8.0) 64  (22 – 102) 1996-2005 
Denmark/males 568 6.4  (4.7 – 8.0) 55  (21 – 102) 1996-2005 
Israel/females 207 7.5  (6.5 – 8.7) 30  (29 – 32) 1990 
Israel/males 413 7.3  (6.1 – 8.6) 30  (29 – 32) 1990 
USA/females 3187 6.8  (5.5 – 8.2) 62  (32 – 83) 1992-1996 
USA/males 2539 6.6  (5.4 – 7.9) 62  (33 – 84) 1992-1996 
Italy/females 284 6.0  (4.3 – 7.7) 60  (24 – 101) 2004 
Italy/males 264 6.1  (4.6 – 7.6) 54  (23 – 96) 2004 
UK/females 3200 7.0  (5.8 – 8.4) 49  (22 – 71) 1998 




Characteristics DC Relatives 
Number (male:female) 23 (16:7) 45 (18:27)* 
Age (years)  
  Mean±SD 30.8±15.4 38.4±17.2 
  Median (range) 30.3 (7.4-71) 40.6 (7.7-69.4) 
LTL (kb)  
  Mean±SD 4.99±0.79 6.49±0.71 
  Median 4.66 (3.83-6.55) 6.55 (4.51-7.86) 
DC, dyskeratosis  congenita;  LTL,  leukocyte  telomere  length;  *6  relatives of DC 
patients for whom the causative mutation is unknown displayed mean=6.96 kb, 
median=7.2 kb (range=5.59‐7.86 kb). 



























1. Chen,  W,  et  al.  Longitudinal  versus  cross‐sectional 
evaluations  of  leukocyte  telomere  length  dynamics: 




Figure S1. Observed LTL attrition distributions after approximately 12  (5th ‐ 95th percentile: 11.2‐
17.8) years along with theoretical distributions (one with‐ and one without measurement error).
The observed LTL attrition distribution  is  from whites of European descent  [1]. The  theoretical distribution  is
based on assumed yearly independent gamma distributed attrition (in bp) with shape parameter 0.4 and scale
parameter 75 (these values have been chosen such that the 10‐year attrition distribution has mean 300 bp and
SD  150  bp).  The  theoretical  curve  is  based  on  the  actual  follow‐up  times  observed  in  the  study  [1]  (each
observation time  is turned  into 5000 simulations, from which the theoretical curve  is found by kernel density
estimation). The  theoretical  curve with noise  is generated by  further adding normally distributed noise with
mean zero and SD 74. The choice of SD 74 is based on the estimated intra‐assay SD for the study (1). 
